Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts.

ABSTRACT:

Objectives

To assess predictive factors for rheumatoid arthritis interstitial lung disease (RA-ILD) in two early rheumatoid arthritis (RA) inception cohorts with a focus on methotrexate (MTX) exposure.

Design

Multicentre prospective early RA inception cohort studies; the early RA study (ERAS) and the early RA network (ERAN).

Setting

Secondary care, ERAS nine centres, ERAN 23 centres in England, Wales and Ireland.

Participants

Patients with new diagnosis of RA, n=2701. Standardised data including demographics, drug therapies and clinical outcomes including the presence of RA-ILD were collected at baseline, within 3-6 months, at 12 months and annually thereafter.

Primary and secondary outcome measures

Primary outcome was the association of MTX exposure on

SUBMITTER: Kiely P 

PROVIDER: S-EPMC6501950 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature